World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
103
Citations
33323
World Ranking
7439
National Ranking
285

Tom W. J. Huizinga publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Tom W. J. Huizinga sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 560 publications — 67th percentile

67% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Tom W. J. Huizinga D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Tom W. J. Huizinga sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 103 D-Index — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Tom W. J. Huizinga is affiliated with Leiden University Medical Center in the Netherlands. Their research primarily focuses on medicine, with a significant contribution to the field of rheumatology.

The scientist's work spans multiple subfields of study, including:

  • Rheumatology
  • Pathology and Forensic Medicine
  • Immunology
  • Radiology, Nuclear Medicine and Imaging
  • Genetics

The main topics covered in their research include:

  • Systemic Lupus Erythematosus Research
  • Rheumatoid Arthritis Research and Therapies
  • Monoclonal and Polyclonal Antibodies Research
  • Systemic Sclerosis and Related Diseases
  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Autoimmune and Inflammatory Disorders Research

Tom W. J. Huizinga has published extensively in various scientific venues, with frequent publications in:

  • Annals of the Rheumatic Diseases
  • RMD Open
  • Lara D. Veeken
  • Arthritis Research & Therapy
  • Arthritis & Rheumatology

The scientist often collaborates with other researchers. Frequent co-authors include:

  • René E. M. Toes (50 joint publications)
  • Cornelia F Allaart (33 joint publications)
  • Sytske Anne Bergstra (25 joint publications)
  • Jeska K de Vries-Bouwstra (24 joint publications)
  • Hans Ulrich Scherer (23 joint publications)

Some of their recent papers highlight ongoing research endeavors and include the following:

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update, 2020, Annals of the Rheumatic Diseases
  • An overview of autoantibodies in rheumatoid arthritis, 2020, Journal of Autoimmunity
  • Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis, 2022, Nature Genetics
  • Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial, 2022, The Lancet
  • Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial, 2024, The Lancet

Best Publications

  • Association between weight or Body Mass Index and hand osteoarthritis: a systematic review

    Erlangga Yusuf;Rob G Nelissen;Andreea Ioan-Facsinay;Vedrana Stojanovic-Susulic

  • Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid Arthritis

    Floris A van Gaalen;Jill van Aken;Tom W J Huizinga;Geziena M Th Schreuder

  • Long-Term Impact of Delay in Assessment of Patients With Early Arthritis

    Michael P. M. van der Linden;Saskia le Cessie;Karim Raza;Diane van der Woude

  • The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis.

    Annette H M van der Helm-van Mil;Kirsten N Verpoort;Ferdinand C Breedveld;Tom W J Huizinga

  • Identification of PLOD2 as Telopeptide Lysyl Hydroxylase, an Important Enzyme in Fibrosis

    Annemarie J. van der Slot;Anne-Marie Zuurmond;Alfons F.J. Bardoel;Cisca Wijmenga

  • Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci

    Alexandra Zhernakova;Alexandra Zhernakova;Alexandra Zhernakova;Eli A. Stahl;Eli A. Stahl;Gosia Trynka;Soumya Raychaudhuri

  • Do knee abnormalities visualised on MRI explain knee pain in knee osteoarthritis? A systematic review

    Erlangga Yusuf;Marion C Kortekaas;Iain Watt;Tom W J Huizinga

  • A genetic study on C5-TRAF1 and progression of joint damage in rheumatoid arthritis

    Hanna W. van Steenbergen;Luis Rodríguez-Rodríguez;Ewa Berglin;Alexandra Zhernakova

  • Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force

    Cindy Strehl;Johannes W J Bijlsma;Maarten de Wit;Maarten Boers

  • Quantitative heritability of anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis.

    Diane van der Woude;Jeanine J. Houwing-Duistermaat;René E. M. Toes;Tom W. J. Huizinga

  • The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Methodological Report Phase I

    Julia Funovits;Daniel Aletaha;Vivian Bykerk;Bernard Combe

  • Classification of rheumatoid arthritis: Comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria

    M. P. M. van der Linden;R. Knevel;T. W. J. Huizinga;A. H. M van der Helm-van Mil

  • Rheumatoid arthritis is a heterogeneous disease - Evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues

    Tineke C. T. M. van der Pouw Kraan;Floris A. van Gaalen;Pia V. Kasperkovitz;Nicolette L. Verbeet

  • Extended report: Evidence for treating rheumatoid arthritis to target: results of a systematic literature search

    Monika Schoels;Rachel Knevel;Daniel Aletaha;Johannes W J Bijlsma

  • A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis.

    Judith A. M. Wessels;Sjoerd M. van der Kooij;Saskia le Cessie;Wietske Kievit

  • Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single‐nucleotide polymorphisms in genes coding for folate pathway enzymes

    Judith A. M. Wessels;Jeska K. de Vries-Bouwstra;Bas T. Heijmans;P. Eline Slagboom

  • Antibodies to Porphyromonas gingivalis Are Associated with Anticitrullinated Protein Antibodies in Patients with Rheumatoid Arthritis and Their Relatives

    Carol A Hitchon;Fatiha Chandad;Elizabeth D Ferucci;Annemiek Willemze

  • Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

    Paul Emery;Gerd R Burmester;Vivian P Bykerk;Bernard G Combe

  • An overview of autoantibodies in rheumatoid arthritis

    Myrthe A.M. van Delft;Tom W.J. Huizinga

  • Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.

    Diane van der Woude;Adam Young;Keeranur Jayakumar;Bart J. Mertens

Frequent Co-Authors

René E. M. Toes
René E. M. Toes Leiden University Medical Center
Peter A. Nigrovic
Peter A. Nigrovic Boston Children's Hospital
Leendert A. Trouw
Leendert A. Trouw Leiden University Medical Center
Désirée van der Heijde
Désirée van der Heijde Leiden University Medical Center
Ferdinand C. Breedveld
Ferdinand C. Breedveld Leiden University Medical Center
Lars Klareskog
Lars Klareskog Karolinska Institute
Peter K. Gregersen
Peter K. Gregersen Feinstein Institute for Medical Research
Robert M. Plenge
Robert M. Plenge Bristol Myers Squibb
Soumya Raychaudhuri
Soumya Raychaudhuri Brigham and Women's Hospital
Paul P. Tak
Paul P. Tak GlaxoSmithKline (United Kingdom)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical studies in the USA opens a wide array of online alternatives in the healthcare field. For those aiming to become advanced healthcare providers, accredited online nurse practitioner programs offer the flexibility to balance studies with clinical experience. These programs often appeal to working professionals seeking to upskill without interrupting their careers.

Entry-level practitioners can benefit from affordable online nursing school options, which combine foundational coursework with local hands-on practice. For registered nurses looking to enhance their qualifications, researching what is the cheapest rn to bsn program online can help reduce costs while opening doors to broader clinical roles.

Meanwhile, experienced nurses interested in leadership, education, or research may consider pursuing an online nursing doctorate. These flexible doctoral programs allow you to advance your expertise while staying engaged in the workforce. Exploring these pathways ensures that aspiring healthcare professionals have diverse, accessible options beyond the traditional medical degree route.

Best Scientists Citing Tom W. J. Huizinga

Trending Scientists

Recently Published Articles